Identifying, monitoring and reducing preventable major bleeds in the hospital setting

被引:3
作者
Caraballo, Deborah [1 ]
Spyropoulos, Alex C. [2 ]
Mahan, Charles E. [1 ]
机构
[1] Univ New Mexico, New Mexico Heart Inst, Albuquerque, NM 87102 USA
[2] Univ Rochester, James P Wilmot Med Ctr, Rochester, NY USA
关键词
Preventable; Major bleeds; Hospital-acquired; Anticoagulation-related; PERCUTANEOUS CORONARY INTERVENTION; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; UNFRACTIONATED HEPARIN; TRIAL; BIVALIRUDIN; PROPHYLAXIS; EVENTS; RISK; ANTICOAGULANT;
D O I
10.1007/s11239-012-0819-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent literature describes methods to reduce "preventable" hospital-acquired venous thromboembolism; however, there is a paucity of data on "preventable" bleeding. While risk assessment models exist for both thrombosis and bleeding, these concepts should be differentiated from whether the event was preventable or non-preventable. Here we describe a protocol to identify, monitor, and evaluate anticoagulation-related preventable hospital-acquired major bleeds (PHAMB). This single-center, prospective observational study with retrospective chart review was conducted in 2009 and 2010 to identify anticoagulation-related major bleeding. Eligible anticoagulation-related hospital-acquired major bleeds (HAMB) were further classified as "preventable" or "non-preventable". A total of 229 major bleed episodes were identified of which 188 were excluded due to being community-acquired or non-anticoagulation related major bleeds. Over the 2 year period, five of the 41 HAMB were classified as preventable providing a total incidence of 13 % PHAMB. Three and two of the PHAMB were due to inappropriate dosing and administration of an anticoagulant when contraindications existed, respectively. PHAMB rates decreased from 0.06 in 2009 to 0.04 per 1000 patient days in 2010 (p = 0.62) although this difference was not statistically significant. Raw incidence utilizing Joint Commission methodology demonstrated a 16.7 % rate in 2009 and an 8.7 % rate in 2010. In hospitalized patients, intervention programs may minimize the incidence of anticoagulation-related PHAMB and may maintain similar rates of preventable bleeding over time. Similar programs should be explored prospectively on a larger scale to reduce harm from anticoagulants in the hospital setting.
引用
收藏
页码:7 / 13
页数:7
相关论文
共 25 条
[1]  
[Anonymous], 2011, IMPR QUAL CAR INP HO
[2]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[3]   INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION [J].
BATES, DW ;
CULLEN, DJ ;
LAIRD, N ;
PETERSEN, LA ;
SMALL, SD ;
SERVI, D ;
LAFFEL, G ;
SWEITZER, BJ ;
SHEA, BF ;
HALLISEY, R ;
VANDERVLIET, M ;
NEMESKAL, R ;
LEAPE, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01) :29-34
[4]  
Bullano Michael F, 2005, J Manag Care Pharm, V11, P663
[5]   Venous thromboembolism prophylaxis in acutely ill medical patients:: definite need for improvement [J].
Chopard, P ;
Dörffler-Melly, J ;
Hess, U ;
Wuillemin, WA ;
Hayoz, D ;
Gallino, A ;
Bachli, EB ;
Canova, CR ;
Isenegger, J ;
Rubino, R ;
Bounameaux, H .
JOURNAL OF INTERNAL MEDICINE, 2005, 257 (04) :352-357
[6]   Factors at Admission Associated With Bleeding Risk in Medical Patients Findings From the IMPROVE Investigators [J].
Decousus, Herve ;
Tapson, Victor F. ;
Bergmann, Jean-Francois ;
Chong, Beng H. ;
Froehlich, James B. ;
Kakkar, Ajay K. ;
Merli, Geno J. ;
Monreal, Manuel ;
Nakamura, Mashio ;
Pavanello, Ricardo ;
Pini, Mario ;
Piovella, Franco ;
Spencer, Frederick A. ;
Spyropoulos, Alex C. ;
Turpie, Alexander G. G. ;
Zotz, Rainer B. ;
FitzGerald, Gordon ;
Anderson, Frederick A. .
CHEST, 2011, 139 (01) :69-79
[7]   Determining the In-Hospital Cost of Bleeding in Patients Undergoing Percutaneous Coronary Intervention [J].
Ewen, Edward F. ;
Zhao, Liping ;
Kolm, Paul ;
Jurkovitz, Claudine ;
Fidan, Dogan ;
White, Harvey D. ;
Gallo, Richard ;
Weintraub, William S. .
JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2009, 22 (03) :266-273
[8]   The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial [J].
Fox, Keith A. A. ;
Antman, Elliott M. ;
Montalescot, Gilles ;
Agewall, Stefan ;
SomaRaju, Bhupathi ;
Verheugt, Freek W. A. ;
Lopez-Sendon, Jose ;
Hod, Hanoch ;
Murphy, Sabina A. ;
Braunwald, Eugene .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (23) :2249-2255
[9]   Bivalirudin versus unfractionated heparin during percutaneous coronary intervention [J].
Kastrati, Adnan ;
Neumann, Franz-Josef ;
Mehilli, Julinda ;
Byrne, Robert A. ;
Iijima, Raisuke ;
Buettner, Heinz Joachim ;
Khattab, Ahmed A. ;
Schulz, Stefanie ;
Blankenship, James C. ;
Pache, Juergen ;
Minners, Jan ;
Seyfarth, Melchior ;
Graf, Isolde ;
Skelding, Kimberly A. ;
Dirschinger, Josef ;
Richardt, Gert ;
Berger, Peter B. ;
Schoemig, Albert .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (07) :688-696
[10]   Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacists' intervention study [J].
Khalili, Hossein ;
Dashti-Khavidaki, Simin ;
Talasaz, Azita Hajhossein ;
Mahmoudi, Laleh ;
Eslami, Kaveh ;
Tabeefar, Hamed .
PHARMACY WORLD & SCIENCE, 2010, 32 (05) :594-600